Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2020 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic Immunization against Glioblastoma.
Schijns VEJC, Pretto C, Strik AM, Gloudemans-Rijkers R, Deviller L, Pierre D, Chung J, Dandekar M, Carrillo JA, Kong XT, Fu BD, Hsu FPK, Hofman FM, Chen TC, Zidovetzki R, Bota DA, Stathopoulos A. Schijns VEJC, et al. Among authors: fu bd. Int J Mol Sci. 2018 Aug 27;19(9):2540. doi: 10.3390/ijms19092540. Int J Mol Sci. 2018. PMID: 30150597 Free PMC article. Review.
A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide.
Bota DA, Taylor TH, Lomeli N, Kong XT, Fu BD, Schönthal AH, Singer S, Blumenthal DT, Senecal FM, Linardou H, Rokas E, Antoniou DG, Schijns VEJC, Chen TC, Elliot J, Stathopoulos A. Bota DA, et al. Among authors: fu bd. Front Oncol. 2022 Jun 28;12:934638. doi: 10.3389/fonc.2022.934638. eCollection 2022. Front Oncol. 2022. PMID: 35837107 Free PMC article.
Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts.
Bota DA, Chung J, Dandekar M, Carrillo JA, Kong XT, Fu BD, Hsu FP, Schönthal AH, Hofman FM, Chen TC, Zidovetzki R, Pretto C, Strik A, Schijns VE, Stathopoulos A. Bota DA, et al. Among authors: fu bd. CNS Oncol. 2018 Jul 1;7(3):CNS22. doi: 10.2217/cns-2018-0009. Epub 2018 Aug 29. CNS Oncol. 2018. PMID: 30157683 Free PMC article. Clinical Trial.